[Onset of type 1 diabetes mellitus during combination therapy of chronic hepatitis C with interferon-alpha and ribavirin].
Christensen
Ulla Bjerre
UB
H:S Hvidovre Hospital, Klinisk Forskningsenhed, Infektionsmedicinsk Afdeling. ulbj@dadlnet.dk
Krogsgaard
Kim
K
D000998:Antiviral Agents / Q000009:adverse effects*; D015551:Autoimmunity; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced* / Q000276:immunology; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D012254:Ribavirin / Q000009:adverse effects*
D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin